Open Label, Randomized, Cross-over Study to Explore the Pharmacokinetics of BAY1834845 After Oral and Intravenous Dosing, Including Food Effect and Absolute Bioavailability (Part A), and to Investigate the Effect of BAY1834845 on the Pharmacokinetics of Orally Administered Methotrexate (Part B) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2018
At a glance
- Drugs BAY 1834845 (Primary) ; BAY 1834845 (Primary) ; Methotrexate
- Indications Pelvic inflammatory disorders; Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Bayer
- 10 Aug 2018 Status changed from active, no longer recruiting to completed.
- 05 Jul 2018 Planned End Date changed from 15 Jun 2018 to 10 Jul 2018.
- 08 Jun 2018 Planned End Date changed from 10 May 2018 to 15 Jun 2018.